2009•Current Opinion in OphthalmologyRequires access

Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration

V. Swetha E. Jeganathan, Nitin Verma

Abstract

PURPOSE OF REVIEW: To report the safety and efficacy of intravitreal injections for age-related macular degeneration (AMD). RECENT FINDINGS: Injecting antivascular endothelial growth factor drugs into the vitreal cavity brings new hope to many AMD patients. Currently, several antivascular endothelial growth factor drugs such as pegaptanib, ranibizumab, and bevacizumab are used via the intravitreal route for neovascular AMD. However, these injections are not without ocular or systemic complications. SUMMARY: Review of current literature suggests that intravitreal antivascular endothelial growth factor agents are generally a safe and effective treatment for neovascular AMD for up to 2-3 years. Presently, there is level I evidence to substantiate this conclusion for pegaptanib and ranibizumab, but not bevacizumab.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 39 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Pegaptanib, Macular degeneration, Medicine, Ranibizumab, Bevacizumab, Ophthalmology, Vascular endothelial growth factor, Choroidal neovascularization